Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of biweekly (every other week) bevacizumab followed by gemcitabine
then infusional 5-fluorouracil in patients with stage III or IV pancreatic cancer. Patients'
response will be evaluated every 8 weeks using usual CT scanning techniques. RECIST (Response
Evaluation Criteria in Solid tumors) criteria will be applied to evaluate response. Tumor
marker levels (Ca 19-9) will be assessed every 4 weeks, but will not be used to measure
response.